Company profile
Ailsevax Limited
AilseVax
Ailsevaxis based on the 3 core elements: neo-antigens discovery, cancer vaccine development, effective adjuvants and delivery platforms. AilseVax are developing innovations across all three domains to develop the next generation of cancer vaccine therapies.Founded by oncologists, immunologists, data scientists and an experienced management team with excellent track-record in building multiple successful life sciences ventures.
Company events
Reference milestones and recent Companies House filing stream events.
Accounts due
Accounts DueNext accounts due date
Confirmation statement due
Confirmation DueNext confirmation statement due date
Confirmation statement filed
ConfirmationLast confirmation statement made up date
Accounts filed
AccountsLast accounts made up date
Accounts With Accounts Type Total Exemption Full
Accounts Awaiting analysisAA | Transaction MzQzNzU0ODU0MmFkaXF6a2N4
Published 27 Sep 2024 03:03
Incorporated
InceptionCompany registered at Companies House
Spinout profile
Company description
AilseVax develops technology, such as an antigen discovery platform and adjuvant technology, with the aim to create new cancer vaccines.
New spin out company from QUB and TCD to develop next generation cancer vaccines
Project impact
N/A
Public funding
Projects
Antigen-to-Surface Enhancement Technology (ASET); an antigen presentation boosting platform for mRNA vaccines
1 Jun 2024 to 30 Nov 2025
The success of mRNA vaccines against SARS-CoV-2 highlights the revolutionary capabilities of this technology. Its efficacy in combatting other diseases like malaria and respiratory syncytial virus is also ground-breaking, and these advancements are now helping to fuel the development of mRNA-based vaccines targeting cancer. However, despite their promise,...
Scaling a novel nanoparticle vaccine adjuvant for clinical development
1 May 2024 to 31 Mar 2025
AilseVax Ltd is a vaccine-focussed company developing new innovations in vaccine design and formulation. AilseVax is a spinout micro-company from Queen's University Belfast trading in Belfast. Up to this point, AilseVax has been focussed on the generation of novel cancer vaccines. In the lead up to this current application, AilseVax has developed an excit...
AltRNA8V antigens for Cancer Vaccines
1 May 2022 to 30 Apr 2024
The COVID pandemic has unsurprisingly awakened new interest in the power of vaccine technologies. One disease area where vaccination holds particular promise is cancer. Cancer remains a major problem, with one in every two people in the UK now predicted to get cancer in their lifetimes. This has a considerable impact on individual lives and livelihoods, e...